WEBINAR: Commercialization in Bioengineering: Starting with the Need and Not the Technology

Traditionally, innovation has started with technology looking for a need. However, the complexities and variety of stakeholders involved in commercialization in biomedical technology call for a different approach - to lead with the need.

August 20, 2018

 

Innovation in the biomedical field is coming from a new perspective. At the Stanford Byers Center for Biodesign, today’s bioengineering vanguards are trained to select, research and categorize needs before embarking on the process of inventing. This approach is increasing productivity and helping to better meet the unique needs of the health technology community. Join Gordon Saul, executive director, as he explores the process of need-led biodesign and discusses real world applications of this methodology. 

Commercialization in Bioengineering: Starting with the Need and Not the Technology
Thursday, August 30, 2018
1:00 PM EST

REGISTER NOW

This goal-oriented approach to research and development marks a new point of view for the bioengineering community. In this webinar, participants will have the opportunity to engage and discuss commercialization, needs-led design, and the complexities of health technology. Questions to be addressed will include: 

  • What is a fundamental mistake made in university translational research?
  • Why is innovation in health technology much more complicated than innovation across other domains?
  • What are the ideal characteristics of a health technology innovation team?
  • What emerging innovation processes from academia have been adopted by major health technology companies?
  • How do health economic factors inform health technology innovation?

REGISTER NOW

About the Presenter: 

Gordon Saul is the executive director of the Stanford Byers Center for Biodesign and an adjunct professor of bioengineering. He has more than 25 years of startup and business development experience in the medical device and pharmaceutical industries. Prior to joining Biodesign, Saul was an executive-in-residence at InterWest Partners, a leading Silicon Valley venture capital firm, where he served as a founding or interim executive in over a dozen portfolio companies. Additionally, he was a co-founder, board member and senior vice president of business development for PowderJect Pharmaceuticals, a publicly-traded drug delivery company acquired by Chiron Corporation in 2003. He also held business development roles at ALZA Corporation and Advanced Cardiovascular Systems, a division of Guidant Corp. Gordon received an AB in engineering sciences from Dartmouth College and an MBA from Stanford.